Atia Naim

Vice President, Corporate Development

Atia Naim is a Vice President of Corporate Development at Raven. Atia’s primary responsibility is to focus on company creation and strategy. Prior to Raven, Atia most recently served as Vice President of Corporate Development at Capstan Therapeutics, which was acquired by AbbVie in 2025. Prior to Capstan, she held roles of increasing responsibility at Coherus Biosciences, where she contributed to the licensing partnership with Junshi Biosciences for toripalimab, and at Genentech, where she began her career in biologics process development. Atia brings 17 years of experience in the biopharma industry spanning technical development, program leadership, alliance management, and corporate development. Atia holds a MS in Bioengineering from Stanford University and a BS in Biotechnology from Vellore Institute of Technology.